Subcutaneous mosunetuzumab with step-up dosing plus six cycles of polatuzumab vedotin enabled fully outpatient delivery without mandatory hospitalization, aligning with access and cost-reduction goals ...

ORR and 61.8% MRR achieved in heavily pretreated population with median duration of response of 17.8 monthsFDA-requested dataset with ...

Hello, and welcome to Nuvation Bio's First Quarter 2026 Financial Results and Corporate Update Call. Today's call is being recorded, and a replay will be available on the company's website. [Operator ...

Company positions itself as the central research hub for patients, clinicians, and compounding pharmacies tracking the ...

Biomarkers are redefining how oncology trials are designed, shifting from single-mutation targeting to comprehensive genomic profiling that enables more precise, patient-centric approaches. In this ...

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...

(UroToday.com) The 2025 European Society for Medical Oncology (ESMO) Annual Congress was host to a presidential symposium. Dr. Jun Guo presented the results of a trial of disitamab vedotin + ...

1 Department of Emergency Medicine, University of Kansas Hospital, Kansas City, Kansas, USA 2 Department of Emergency Medicine, Wayne State University, Detroit, Michigan, USA 3 Cardiovascular Research ...

The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results. This is an ASCO Meeting Abstract from the 2022 ASCO Annual Meeting I. This abstract does not ...

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia: Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age Safety and efficacy of polatuzumab vedotin with ...

Facebook Pages provide a way for consumers to connect to your business. The key to getting visits to the Page is building a community of readers who have a reason to return. Using subgroups helps ...